Deletion or pharmacological inhibition of CK1α is also detrimental to MM cells, indicating that lenalidomide-dependent degradation of CK1α may contribute to its anti-myeloma activity [59,60,61]. This evidence concerns the gene CSNK1A1 and plasma cell myeloma.